Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | LAP3 | P28838 | 1/20 | 0.47 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297107 | 1.00 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2309825 | 0.95 | SLC7A5 (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2309818 | 0.95 | SLC7A5 (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17874602 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL12928633 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL14095437 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL15679078 | 0.87 | ALPI (0.66) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL26359430 | 0.87 | ALPI (0.66) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2436027 | 0.87 | SLC7A5 (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL25982909 | 0.87 | SLC7A5 (0.53) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1119340-C | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2003-08-27 | — | — | CN | claimed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
| CN-1942161-B | Compositions and treatments for demyelinating diseases and paralysis by administration of remyelinating drugs | ELAN PHARM INC | 2012-05-30 | — | — | CN | disclosed |
| US-8030513-B2 | Rheology control agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100204376-A1 | Rheology Control Agents | AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) | 2010-08-12 | — | — | US | disclosed |
| US-7741510-B2 | Rheology control agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1838749-A1 | COATING COMPOSITIONS CONTAINING RHEOLOGY CONTROL AGENTS | E.I.Du pont de nemours and company (US) | 2007-10-03 | — | — | EP | disclosed |
| CN-1942161-A | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | ELAN PHARM INC (US) | 2007-04-04 | — | — | CN | disclosed |
| WO-2006076715-A1 | COATING COMPOSITIONS CONTAINING RHEOLOGY CONTROL AGENTS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155021-A1 | Coating compositions containing rheology control agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-20060155146-A1 | Rheology control agents | AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) | 2006-07-13 | — | — | US | disclosed |
| CN-1119340-C | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155146-A1 | Rheology control agents | HCRTR1, HCRTR2, REL | ALPI 4721/4885PKM 1715/4885PTGS1 3776/4885 |
| US-20100204376-A1 | Rheology Control Agents | HCRTR1, HCRTR2, REL | ALPI 4721/4885PKM 1715/4885PTGS1 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.